To Predict Anti-Inflammatory and Immunomodulatory Targets of Guizhi Decoction in Treating Asthma Based on Network Pharmacology, Molecular Docking, and Experimental Validation
Open Access
- 20 December 2021
- journal article
- research article
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2021, 1-17
Abstract
Asthma, characterized by the continuous inflammatory response caused by a variety of immune cells, is one of the most common chronic respiratory diseases worldwide. Relevant clinical trials proved that the traditional Chinese medicine formula Guizhi Decoction (GZD) had multitarget and multichannel functions, which might be an effective drug for asthma. However, the effective ingredients and mechanisms of GZD against asthma are still unclear. Therefore, network pharmacology, molecular docking, and cell experiments were performed to explore the antiasthma effects and potential mechanisms of GZD. First, we applied the TCMSP database and literature to obtain the bioactivated ingredients in GZD. SwissTargetPrediction, TCMSP, GeneCards, OMIM, PharmGkb, TTD, DrugBank, and STRING database were used to get core genes. In addition, the key pathways were analyzed by the DAVID database. Molecular docking was used to predict whether the important components could act on the core target proteins directly. Finally, qPCR was carried out to verify the network pharmacology results and the possible mechanisms of GZD in the treatment of asthma. We collected 134 active ingredients in GZD, 959 drug targets, and 3223 disease targets. 431 intersection genes were screened for subsequent analysis. Through GO and KEGG analyses, enriched pathways related to inflammation and immune regulation were presented. Through the qPCR method to verify the role of essential genes, we found that GZD had an excellent anti-inflammatory effect. Direct or indirect inhibition of MAPK and NF-κB pathways might be one of the crucial mechanisms of GZD against asthma. GZD might be a promising potential drug for the treatment of asthma. This article provided a reference for the clinical application of GZD.Keywords
Funding Information
- National Basic Research Program of China (2019YFC1710105)
This publication has 47 references indexed in Scilit:
- SPA0355 suppresses T-cell responses and reduces airway inflammation in miceEuropean Journal of Pharmacology, 2014
- Fragment ion diagnostic strategies for the comprehensive identification of chemical profile of Gui-Zhi-Tang by integrating high-resolution MS, multiple-stage MS and UV informationJournal of Pharmaceutical and Biomedical Analysis, 2014
- Melatonin inhibits MUC5AC production via suppression of MAPK signaling in human airway epithelial cellsJournal of Pineal Research, 2014
- Phellinus linteusExtract Exerts Anti-asthmatic Effects by Suppressing NF-κB and p38 MAPK Activity in an OVA-induced Mouse Model of AsthmaImmune Network, 2014
- Combining Machine Learning Systems and Multiple Docking Simulation Packages to Improve Docking Prediction Reliability for Network PharmacologyPLOS ONE, 2013
- Reciprocal effects of Guizhi decoction (桂枝汤) to the Guizhi decoction syndrome by toll-like receptor mRNA expression and cytokines secretionChinese Journal of Integrative Medicine, 2013
- The tyrosine phosphatase, SHP-1, is involved in bronchial mucin production during oxidative stressBiochemical and Biophysical Research Communications, 2010
- The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancerExpert Opinion on Investigational Drugs, 2009
- The growth plate sparing effects of the selective glucocorticoid receptor modulator, AL-438Molecular and Cellular Endocrinology, 2007
- Genes, environments, development and asthma: a reappraisalEuropean Respiratory Journal, 2006